Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00532025 | Sorafenib in Resected Non-small Cell Lung Carcinoma(SIRN) | terminated | Phase 2 | 134 | Johannes Gutenberg University MainzOTHER | 1 | Jul 28, 2009 | clinicaltrials |
| NCT00234442 | Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer | terminated | Phase 2 | 47 | AstraZenecaINDUSTRY | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00383331 |
| Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer |
| terminated |
| Phase 2 |
| 19 |
| Eli Lilly and CompanyINDUSTRY |
| 1 |
| Jun 3, 2009 |
| clinicaltrials |
| NCT00259285 | Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer | terminated | Phase 2 | 10 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 2, 2009 | clinicaltrials |
| NCT00174369 | MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 34 | PfizerINDUSTRY | 1 | Mar 17, 2009 | clinicaltrials |
| NCT00161278 | Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling | terminated | Phase 2 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 30, 2008 | clinicaltrials |
| NCT00535015 | Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer | terminated | Phase 2 | 70 | AnaborexINDUSTRY | 2 | Jul 22, 2008 | clinicaltrials |
| NCT00263016 | Docetaxel in Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 50 | SanofiINDUSTRY | 1 | Mar 20, 2008 | clinicaltrials |
| NCT00061646 | Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 25 | AbbottINDUSTRY | 1 | Aug 14, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Jul 28, 2009source: clinicaltrials